The guests who participated in the recording included Zhu Yi, founder and chairman of Baili Tianheng, Zou Jianjun, executive director and CEO of Junshi Biosciences, Fang Jianmin, co-founder and CEO of Remegen, and Liu Datao, chairman and CEO of Mabwell. Luo Jiarong, chief analyst of GF** biomedical industry, hosted this episode.
"Shanghai Market Hui Hard Science and Technology Hard Guest" is a high-end interview column jointly launched by Shanghai ** Exchange and CCTV, aiming to provide a communication platform for outstanding people in the field of "hard technology" and promote the continuous improvement of the ecology of the industrial chain of the Science and Technology Innovation Board.
In 2023, China's biopharmaceutical industry will usher in a wave of "sweeping" by multinational companies. Zhu Yi said that this reflects the achievements of China's biomedical ecological development and shows that China's innovative technologies and projects have been recognized globally. Zou Jianjun believes that the scientific and technological content of China's innovative drugs has been recognized by more and more large enterprises, and more Chinese innovative drugs will go to the world stage in the future.
Looking back on 2023, it is known as the "first year" of a bumper harvest of domestic innovative drugs. Liu Datao introduced that the number of innovative drug approvals in China has increased significantly, with more than 22 billion yuan of external authorizations, and the number of innovative drugs listed has increased by 74%. The companies have achieved fruitful results, such as the first overseas transaction of Baili Tianheng, which totaled US$8.4 billion.
On the issue of pricing, there is a gap between China and the United States dozens of times. Zou Jianjun explained that this difference stems from different payment systems and differences in per capita medical investment. Liu Datao added that China's pharmaceuticals are relatively low, but the medical investment is also relatively low, so the difference is within a reasonable range.
Faced with the dilemma of no profit for new products, the guests proposed solutions. Fang Jianmin suggested separating the first-class systems of innovative drugs and generic drugs, and allowing companies to set their own prices; Zhu Yi suggested that some innovative drugs should be priced in the market on the basis of medical insurance payment; Liu Datao believes that it is necessary to solve the problem of drug accessibility and encourage business model innovation and the development of private hospitals.
Regarding the issue of innovative drugs entering the market, Fang Jianmin said that all departments and enterprises need to work together to solve it. Zou Jianjun believes that enterprises need to be supported from the policy level to overcome the "last mile" problem. Zhu Yi emphasized that China should create a low-price market to make innovative drugs reasonable.
Regarding the issue of "2024 Pharmaceutical Track", the guests had different views. Liu Datao believes that the pharmaceutical industry will not become the protagonist and is at a relatively low ebb. Fang Jianmin believes that there are still investment opportunities in the pharmaceutical industry, especially during the trough period. Zhu Yi is optimistic about the development of the ADC field and pointed out that ADC is expected to change the pattern of tumor **.
To sum up, China's innovative drug industry is facing challenges, but it is still full of hope. Issues such as policy support, market pricing, and the opening of the pharmaceutical market need to be comprehensively implemented. In the future, continuous innovation and policy support will promote the innovative drug industry to a broader development path. What are your thoughts on the future of China's innovative drug industry?